Dedicated to AAT therapeutics for Respiratory diseases
Of high medical need with global societal impact
AATec Medical is a biotech company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. We have successfully demonstrated proof-of-principle in several indications and are preparing for a proof-of-concept clinical trial with inhaled AAT in respiratory applications.
We were founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical drug development and product industrialization. The team provides a comprehensive biomedical and industrial skill set based on long term expertise to drive the research, product development, and clinical testing of our product pipeline.
Dr. Rüdiger JankowskyCEO and Co-founder
Rüdiger has more than 20 years of experience in the biotech industry and is a seasoned leader with comprehensive expertise in product development and regulatory approval. He served as CEO for several life science start-ups, built interdisciplinary expert organizations for R&D and biotech licensing and was instrumental in the development, regulatory approval, and partnering of multiple biopharmaceuticals.
PD Dr. Manfred StanglCSO and and Co-founder
Manfred is Director Physician of the renal and pancreas transplant unit at the University Clinic of Munich, with decades of experience in medical and biopharmaceutical research. He previously founded Apceth Biopharma, a biotech company for the manufacturing of stem cells which was acquired by Hitachi in 2018.
Dr. Michael StrassmairCMO and Co-founder
Michael is Director Physician at the Manu Sana clinic in Starnberg/Munich and has many years of experience in clinical studies. He is working on the strategic determination of target indications of our products and is preparing clinical development strategies in conjunction with regulatory activities.
Dr. Karsten OttenbergChair of the Advisory Board and Co-founder
Karsten is the former CEO and Executive of multinational corporates including the BSH Home Appliances Group, Giesecke & Devrient and Philips Semiconductors (now NXP). Karsten brings his global experience in strategy, innovation, industrial scaling and business management to our team. He also acts as a mentor for impact scale-ups on global platforms such as Endeavor and The Unreasonable Group.
Willem BulthuisMember of the Advisory Board and Co-founder
Willem Bulthuis is dedicated since 2015 to supporting global venturing ecosystems, as co-founder, board member and advisor at ventures, as business angel, as venture partner at VC Funds. His focus is on deeptech and sustainability topics like transport, energy, recycling, construction, and health. Willem brings over 30 years of executive experience at global high-tech corporations like Philips Electronics, NXP Semiconductors, G&D and Secunet, as Global Sales Executive, CTO and Member of the Board. He lived in Europe and Silicon Valley and is based in Munich since 2010.
Prof. Burkhard SträterMember of the Advisory Board
Burkhard is specialized in regulatory affairs and pharmaceutical law. He founded his lawfirm in 1987, advising pharmaceutical companies and medical device manufacturers on clinical development, national and European marketing authorization and pharmacovigilance for drugs and medical devices. As a leading European expert in his field, Burkhard became Head of the Board of Studies and Examinations at the University of Bonn, Germany in 2008. He is continuously providing advanced management training for the pharmaceutical industry and healthcare institutions.